Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
160
resultados
Última actualización
07/09/2025 [07:26:00]
Resultados 125 a 150 de 160
Resumen de: CN119724354A
The invention discloses a screening method and application of an ulcerative colitis biomarker, EPHX2 can be used as a biomarker for ulcerative colitis detection, provides a new technical means for ulcerative colitis detection, diagnosis, treatment and prognosis evaluation, provides a new direction for research of UC pathogenesis, and provides a new application prospect. And a new possibility is provided for clinical treatment.
Resumen de: WO2025064813A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Resumen de: US2025104866A1
A method for determining a pathological parameter (e.g., a microvilli length (MVL)) of a subject is used to determine a therapeutic response for treatment of the subject. The method includes receiving a pathology image of the subject, identifying a pathological feature and determining a parameter of that feature (e.g., MVL), and determining an aggregate parameter. The pathology image may be pre-processed and/or segmented into regions of interest. The entire pathology image and/or the segmented regions may be subject to feature annotation.
Resumen de: WO2025064645A1
The invention relates to diagnostic and therapeutic methods for inflammatory bowel disease (IBD) and to physiologically acceptable compositions of isolated bacterial strains, lysates thereof, and supernatants therefrom for use in treating IBD.
Resumen de: CN119255775A
A defecation detection and alert system includes a sensing device mounted to an absorbent article for alerting a caregiver of the presence of solid excreta by analyzing gas expelled from the absorbent article during defecation. The system includes an elongate conduit made of a flexible material and mounted to an absorbent article. The pipeline is connected to a gas sensor arranged in the hanging device, and the gas sensor determines whether defecation occurs in the absorption product or not by detecting existence of hydrogen sulfide gas.
Resumen de: CN119693421A
The invention discloses a mouse intestinal peristalsis speed detection method and device based on a fluid dense optical flow algorithm, and the method specifically comprises the steps: carrying out the dyeing imaging of a mouse intestinal tract, and shooting a mouse intestinal peristalsis video; carrying out calculation region framing on the complete mouse intestine peristalsis video, extracting an intestine region contour of the mouse, and framing a rectangular image region needing to be calculated; the method comprises the following steps: preprocessing a mouse intestine peristalsis video, filtering breathing frames frame by frame, marking frames influenced by breathing as invalid frames, and skipping in subsequent optical flow calculation; performing optical flow calculation: circularly reading every two frames of the video, and obtaining a group of optical flows after respiration influence is eliminated by using a fluid-based dense optical flow algorithm; and (n-1) groups of optical streams obtained by the n frames of videos are superposed along a time axis to obtain an optical stream index at each pixel point in the whole intestinal region so as to determine the intestinal peristalsis speed of the mouse. The mouse intestinal tract can be monitored in real time and repeatedly evaluated, and theoretical support is provided for diagnosing inflammatory bowel diseases and discovering potential therapeutic drugs.
Resumen de: CN119685466A
The invention discloses an application of DUOX2 in identification of ileum subtype and colon subtype Crohn's disease. A group of new DUOX2-epi is analyzed and identified based on single cell transcriptome sequencing, the proportion of the cells in the Crohn disease inflammation tissue is obviously increased, and the proportion of the DUOX2-epi in the colon type Crohn disease inflammation tissue is obviously higher than that in the ileum type Crohn disease inflammation tissue; in addition, in ileum type and colon type Crohn diseases, interaction with surrounding cells is carried out through different mechanisms, so that the occurrence and development of the diseases are promoted. Therefore, based on a DUOX2-epi mediated intercellular communication network, a gene prediction module for predicting different subtypes of Crohn diseases and evaluating the treatment effect of a biological agent is developed, and based on a DUOX2 molecular network, an experimental basis and a research direction are provided for subsequent in-depth research, and a new strategy is expected to be provided for diagnosis and treatment of different subtypes of Crohn diseases.
Resumen de: CN119666500A
The invention provides a biomarker for predicting whether an individual suffers from progression-stage adenoma or not and application of the biomarker. Proteins with significantly different abundance levels in blood of patients and healthy control people at different stages in the colorectal cancer tumor process (inflammatory disease-benign polyp-progression-stage adenoma-colorectal cancer) are analyzed, and a plurality of protein markers capable of being used for progression-stage adenoma risk prediction are screened out. On one hand, a dichotomy algorithm is adopted, a model is built based on a random forest, good performance is shown in distinguishing of progression-stage adenoma and healthy control, the AUC value reaches 0.807, and high diagnostic value is achieved; a six-classification algorithm is further adopted, a model is constructed through gradient lifting, progressive-stage adenoma, early-stage colorectal cancer, benign polyp, inflammatory bowel disease, other cancers and healthy people can be effectively distinguished, the accuracy of the model is 0.78, the consistency is 0.729, the diagnosis sensitivity of the progressive-stage adenoma is 73.4%, and the specificity is 94.7%; and a new way is provided for progression stage adenoma diagnosis.
Resumen de: US2025090497A1
Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P1) receptor-associated disorder comprising prescribing and/or administering to an individual in need thereof a standard dose of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopentabindol-3-yl)acetic acid (Compound 1), or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Resumen de: EP4523694A1
The present disclosure relates to: a method, a composition, and a method for producing the same for treating IBD using gastrointestinal contents or excretions modified with an IgA antibody; a method for obtaining an IgA antibody that restores the bacterial flora in the gastrointestinal tract of an IBD patient; a method, a composition, and a method for producing the same for modifying gastrointestinal contents or excretions of an IBD patient using an IgA antibody; and a method, a composition, and a method for producing the same for testing with the diagnostic pharmaceutical drug containing an IgA antibody in a patient treated with the IBD therapeutic agent containing gastrointestinal contents or excretions.
Resumen de: CN119639932A
The invention discloses an application of intestinal bacteria in an ulcerative colitis prediction technology, and belongs to the technical field of biology, and the intestinal bacteria are Alistipes finegoldii; the method comprises the following steps: detecting the relative abundance of Alistipes finegii in an excrement sample of a patient, and using the low relative abundance of Alistipes finegii to predict the disease activity of ulcerative colitis; according to the application disclosed by the invention, not only is the association between the Alistipes finegili and the UC disease activity verified, but also the potential action mechanism of the Alistipes finegili is further explored. By means of 16s amplicon sequencing and transcriptomics combined analysis, it is found that the Alistipes finegili plays an anti-inflammatory role through an Hsp90/AMPK/ACC signal channel, and the intestinal barrier function is maintained. The invention verifies that a new view angle is provided for the effect of the Alistipes finegili in the UC pathogenesis, and provides a theoretical basis for developing a treatment strategy based on the strain.
Resumen de: CN119613546A
The invention discloses an IL-10 antibody and an application thereof. The anti-human IL-10 monoclonal antibody human IL-10 protein provided by the invention has relatively strong affinity, can be used for detecting the expression of the human IL-10 protein, can also be applied to immunotherapy independently or in combination with other methods, and has diagnosis and treatment values in tumors, inflammatory bowel diseases and rheumatism immune diseases.
Resumen de: CN119619519A
The invention relates to application of a C7orf10 protein level detection agent in preparation of a mitochondrial disease diagnostic agent. Research finds that C7orf10 protein level rise is shown in cells with mitochondrial dysfunction caused by different gene defects and in the body of a patient, which indicates that the C7orf10 protein level rise can be used as a molecular marker of the mitochondrial dysfunction, so that a C7orf10 protein level detection agent can be used as a mitochondrial disease diagnosis agent, and the clinical application prospect is wide. Therefore, a novel diagnosis method and a novel diagnosis reagent are provided for diagnosis of mitochondrial diseases.
Resumen de: US2025084174A1
The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: US2025084480A1
Disclosed are methods for treating active eosinophilic colitis (EoC), or in certain aspects, inflammatory bowel disease (IBD), in an individual in need thereof. In one aspect, the methods may comprise a) assaying a tissue sample obtained from a colon of an individual who may be in need of such treatment, wherein the assaying comprises detecting expression of one or more gene of a transcriptome gene set; b) calculating a score based on the expression of one or more gene of a transcriptome gene set; and c) selecting a tissue sample that exhibits a score indicative of EoC or IBD. The methods may further comprise administering an EoC or IBD therapy to the individual whose tissue sample exhibited a score indicative of having EoC or IBD.
Resumen de: CN119591712A
A fully humanized mouse is immunized by using a BDCA-2 extracellular domain (ECD) antigen, positive clones are screened out through a hybridoma technology, and the specific monoclonal antibody targeting human plasma cell-like dendritic cells is obtained through gene sequencing and recombinant expression purification. The antibody disclosed by the invention has high binding capacity to human BDCA-2, and can be used for developing drugs or diagnostic reagents for treating or preventing inflammatory diseases or autoimmune diseases.
Resumen de: CN119587515A
The invention belongs to the field of biological medicines, and particularly relates to application of nordihydroguaiamic acid and derivatives thereof in preparation of products for treating inflammatory bowel diseases. By exogenous supplementation of nordihydroguaiamic acid (NDGA), DSS-induced mouse enteritis is remarkably relieved, survival prognosis of mice is improved, mucosal barrier dysfunction of UC mice is remarkably improved, the number of inflammatory macrophage subgroups is reduced, transcription generation of colon tissue proinflammatory factors and activated cleavage of pyroptosis-related proteins are inhibited, and the application of the NDGA is developed. Good anti-inflammatory effect and intestinal protection effect are achieved. The NDGA is further found to be capable of remarkably improving the mucosal barrier function disorder of the UC mouse, and the NDGA is prompted to have a good intestinal protection effect; the NDGA can inhibit the transcriptional generation of IL-1beta by regulating and controlling the NR4A1-Serpin1 pathway and reduce the co-localization of NR4A1 and NLRP3 in macrophages, which prompts that the NDGA can regulate and control the interaction relationship of NR4A1 and NLRP3 to inhibit inflammation.
Resumen de: WO2024008796A1
The present invention relates to a sandwich immunoassay for detecting in a biological sample cross-linked Collagen Type V, and its use in identifying patients with conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing the sandwich immunoassay.
Resumen de: CN119591705A
The invention discloses an anti-hemoglobin antibody and application thereof, and relates to the field of antibodies. The anti-hemoglobin antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for hemoglobin detection, and has good activity and sensitivity.
Resumen de: CN119560000A
The invention provides an irritable bowel syndrome intestinal microbial marker, application thereof and a method for constructing a detection model, and belongs to the technical field of medicine and biomedicine. By utilizing the irritable bowel syndrome intestinal microbial marker, the association between the marker level and IBS symptom severity, the life quality of a patient and the treatment effect can be evaluated, and personalized diet, prebiotics, probiotics or antibacterial drugs and other treatment suggestions are provided for the patient according to the specific intestinal microbial marker composition of the patient. According to the invention, the accuracy and effectiveness of early auxiliary diagnosis, prognosis and treatment of IBS are improved, the understanding of IBS is deepened, and the development of microbiomics in clinical application is promoted. The AUC value of the irritable bowel syndrome detection model reaches 0.9931, which shows that the classifier has good performance when distinguishing positive and negative samples.
Resumen de: CN119552252A
The invention discloses an anti-TL1A antibody and a preparation method and application thereof in the technical field of biological medicine. The anti-TL1A antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3. The antibody provided by the invention has relatively high affinity and better biological activity characterization, and the epitope is different from that of a traditional anti-TL1A antibody.
Resumen de: TW202509234A
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: CN119541878A
The invention provides a training method and system of an inflammatory bowel disease diagnosis and prediction model based on data driving, a storage medium and electronic equipment, and relates to the technical field of model training. According to the method, the BP feedforward neural network is adopted to process and analyze the standard data of each inspection index extracted from the ultrasonic diagnosis report text, so that the rehabilitation cycle of the patient with the inflammatory bowel disease is predicted. Through training and verification, the model shows high accuracy and reliability, and provides a powerful decision support tool for doctors. In addition, the dynamic adjustment and updating capability of the model ensures that the model can adapt to continuously changing clinical data in practical application, and the application value in personalized treatment planning and disease management is further enhanced.
Nº publicación: CN119529077A 28/02/2025
Solicitante:
东莞市朋志生物科技有限公司
Resumen de: CN119529077A
本发明公开了一种抗血红蛋白的抗体及其应用，涉及抗体领域。本发明公开的抗血红蛋白抗体包括重链互补决定区和轻链互补决定区，该抗体为血红蛋白的检测提供了重要的原料来源，且具有良好的亲和力或活性。
BOPI
Sede Electrónica
